Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders.
Linda Nguyen, Kelan Thomas, Brandon P Lucke-Wold, J. Cavendish, M. Crowe, R. Matsumoto
Pharmacology & Therapeutics March 1, 2016 DOI: 10.1016/j.pharmthera.2016.01.016 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Open-label Peer reviewed |
|---|---|
| Intervention | Dextromethorphan |
| Key findings | The review reports that preclinical and clinical studies suggest dextromethorphan may benefit a range of neurological and psychiatric conditions, including depression, stroke, traumatic brain injury, seizure, pain, methotrexate neurotoxicity, Parkinson's disease, and autism. However, the optimal dose and safety of chronic dosing are not fully known, and the authors propose future research directions. |
Abstract
Dextromethorphan (DM) is a commonly used antitussive and is currently the only FDA-approved pharmaceutical treatment for pseudobulbar affect. Its safety profile and diverse pharmacologic actions in the central nervous system have stimulated new interest for repurposing it. Numerous preclinical investigations and many open-label or blinded clinical studies have demonstrated its beneficial effects across a variety of neurological and psychiatric disorders. However, the optimal dose and safety of chronic dosing are not fully known. This review summarizes the preclinical and clinical effects of DM and its putative mechanisms of action, focusing on depression, stroke, traumatic brain injury, seizure, pain, methotrexate neurotoxicity, Parkinson's disease and autism. Moreover, we offer suggestions for future research with DM to advance the treatment for these and other neurological and psychiatric disorders.
Citations in the library
Cited by 25
- Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences. Psychopharmacology February 1, 2018
- Investigational drugs in recent clinical trials for treatment-resistant depression Expert Review of Neurotherapeutics January 16, 2017
- Novel antidepressant drugs: Beyond monoamine targets CNS Spectrums September 30, 2021
- Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials Expert Opinion on Emerging Drugs January 2, 2021
- Combined NMDA Inhibitor Use in a Patient With Multisubstance-induced Psychotic Disorder Journal of Addiction Medicine February 4, 2018
and 20 more in the library
Cites 10
- NMDA Antagonist Neurotoxicity: Mechanism and Prevention Science December 6, 1991
- Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder JAMA Psychiatry April 16, 2014
- NEUROBIOLOGY OF STRESS, DEPRESSION, AND RAPID ACTING ANTIDEPRESSANTS: REMODELING SYNAPTIC CONNECTIONS Depression and Anxiety March 10, 2014
- High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens. Psychopharmacology September 1, 2012
- Acute cognitive effects of high doses of dextromethorphan relative to triazolam in humans. Drug and Alcohol Dependence March 1, 2013
and 5 more in the library